Fate Therapeutics (FATE) Tops Q4 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c